ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1407

New Clinical Features of Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne Syndrome

Patrycja Hoffmann1, Amanda K. Ombrello2, Deborah Stone3, Anne Jones4, Karyl Barron5 and Daniel Kastner6, 1Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, 2Inflammatory Diseases Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 3NIH/NHGRI, Bethesda, MD, 4NHGRI/NIH, Bethesda, MD, 5National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 6Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch, NIH/NHGRI, Bethesda, MD

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Autoinflammatory Disease and pyoderma gangrenosum

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The dominantly inherited pyogenic arthritis pyoderma gangrenosum and acne (PAPA) syndrome is caused by mutations in PSTPIP1.  It is one of the least understood of the known monogenic autoinflammatory diseases, both from a pathogenic and treatment perspective. Associated symptoms include arthritis, cystic acne, and pyoderma gangrenosum without discernable infection. Therapy revolves around the suppression of the systemic inflammation, typically with corticosteroids, interleukin-1 receptor antagonists, and tumor necrosis factor inhibitors. This abstract documents the continued expansion of clinical manifestations of disease as two PAPA patients have recently presented with the features of noninfectious epiglottitis and sterile osteomyelitis.

Methods: A retrospective medical records review of not previously published rare complications of two patients with PAPA syndrome. Complete histories were obtained and physical exams were performed. Radiographic imaging, complete blood count with differential, CRP and ESR were examined.

Results: One patient with PAPA developed a severe sore throat, which upon further clinical and radiographic evaluation showed piriform sinus swelling consistent with supraglottitis. CRP and ESR were elevated, while WBC was normal. Treatment was initiated with IV clindamycin and ceftriaxone; doxycycline was later added. The patient continued to have severe sore throat and repeat radiographic findings showed ongoing swelling. Clindamycin was stopped and methylprednisolone as well as a scheduled dose of golimumab was initiated with significant improvement in symptoms and normalization of radiographic findings. CRP and ESR improved.

Another patient developed severe right wrist pain and swelling. MRI findings revealed distal right radial epiphysis marrow abnormalities consistent with osteomyelitis without synovitis. ESR and CRP were elevated and WBC was normal. The patient was treated with clindamycin without benefit in symptoms or improvement in MRI findings. Clindamycin was discontinued and methylprednisolone and anakinra were initiated which resulted in decreased pain and improvement in marrow inflammation on MRI. CRP and ESR improved.

Conclusion: Our findings indicate new clinical features in PAPA that include aseptic supraglottitis and non-bacterial osteomyelitis. Improvement in clinical symptoms, radiographic findings, and acute phase reactants as well as a normal WBC support an inflammatory rather than infectious process.


Disclosure: P. Hoffmann, None; A. K. Ombrello, None; D. Stone, None; A. Jones, None; K. Barron, None; D. Kastner, None.

To cite this abstract in AMA style:

Hoffmann P, Ombrello AK, Stone D, Jones A, Barron K, Kastner D. New Clinical Features of Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne Syndrome [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/new-clinical-features-of-pyogenic-arthritis-pyoderma-gangrenosum-and-acne-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-clinical-features-of-pyogenic-arthritis-pyoderma-gangrenosum-and-acne-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology